Synalar N Ointment
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Synalar N Ointment
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Fluocinolone Acetonide Ph. Eur. 0.025% w/w Neomycin Sulphate Ph. Eur. 3250 IU/g
3. PHARMACEUTICAL FORM
Ointment
4. CLINICAL PARTICULARS
4.1. Therapeutic Indications
Synalar N combines the effective topical corticosteroid Synalar with an effective antibacterial agent Neomycin Sulphate Ph Eur.
It is indicated for inflammatory dermatoses including eczema, dermatitis, seborrhoea and intertrigo, where secondary bacterial infection is present or is likely to occur.
4.2. Posology and Method of Administration
A small quantity of Synalar N preparation is applied lightly to the affected area two or three times a day and massaged gently and thoroughly into the skin. These recommendations apply to both children and adults, including the elderly.
If an occlusive dressing is indicated, the affected area should first be thoroughly cleansed. The Synalar N preparation is then applied and covered with a suitable dressing.
Synalar N cream is particularly suitable for very inflamed or weeping surfaces and for flexures of the body, whilst Synalar N ointment is more suitable for dry scaly lesions.
Treatment should not normally be longer than seven days and it is preferable to identify the causative organism.
If used in childhood or on the face, courses should be limited to five days and occlusion in such cases should not be used.
4.3. Contra-indications
Synalar N preparations are contra indicated in primary infections of the skin caused by bacteria, fungi or viruses and in rosacea, acne, perioral dermatitis, and napkin eruptions.
Synalar preparations are not advised in the treatment of children under one year of age. The eyes should be avoided.
Synalar N is contraindicated in those patients with a history of hypersensitivity to neomycin.
Topical neomycin preparations should not be applied to the external auditory canal of patients with perforated eardrums.
4.4. Special Warnings and Precautions for Use
Long term continuous topical steroid therapy can produce local atrophic skin changes and dilation of the superficial blood vessels, particularly when occlusive dressings are used or where skin folds are involved. Prolonged use of topical steroids or treatment of extensive areas, even without occlusion, can result in sufficient absorption of the steroid to produce the features of hypercorticalism and underlying adrenal suppression, especially in infants and children.
In the presence of a viral or fungal infection, the use of an appropriate agent should be instituted. If a favourable response does not occur promptly, Synalar N should be discontinued until the infection has been adequately controlled.
Because of the potential hazard of nephrotoxicity and ototoxicity associated with neomycin, prolonged use or use of large amounts of the product should be avoided in conditions where absorption of neomycin is possible. Care is particularly needed in elderly or renally-impaired patients.
These preparations are not for ophthalmic use.
Treatment should be discontinued if unfavourable reactions are seen.
4.5. Interactions with other Medicaments and other forms of Interaction
Not applicable.
4.6. Pregnancy and Lactation
Pregnancy: There is inadequate evidence of safety in human pregnancy. Topical administration of steroids to pregnant animals can cause abnormalities of foetal development, including cleft palate and intrauterine retardation.
There may therefore be a very small risk of such effects on the human foetus.
Lactation: Topical steroids should not be applied to the breasts prior to nursing. When topical steroid treatment is considered necessary during breast feeding, both the amount applied and the length of treatment should be minimised.
4.7. Effects on Ability to Drive and Use Machines
No precautions are necessary.
4.8 Undesirable effects
As with all topical steroids the occasional patient may develop an adverse reaction. Adverse reactions are listed by system organ class. The frequency of adverse reactions cannot be estimated from the available data.
Immune System Disorders
Local hypersensitivity reactions
Skin and Subcutaneous Tissue Disorders
Dermatitis Perioral dermatitis Acne or worsening of acne Acne rosacea
Extensive treatment, particularly involving occlusive dressings or where skin folds are involved, can result in both local atrophic changes, such as striae, skin thinning and telangiectasia. Mild depigmentation, which may be reversible, hypertrichosis and irreversible striae.
Endocrine Disorders
Adrenal suppression.
General Disorders and Administration Site Conditions
Irritation at the site of application.
Infections and Infestations
The use of topical steroids on infected lesions, without the addition of appropriate anti-infective therapy, can result in the spread of opportunist infections.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system in the United Kingdom: Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard
4.9. Overdose
Accidental ingestion:
The 30g tube of Synalar N contains 7.5mg of the steroid and 150mg of neomycin. No toxic effects are likely to occur even if the full contents of a 30g tube are ingested. Similarly the ingredients of the base are unlikely to have any toxic effect in the quantities in which they occur. Therefore no remedial action is required in the event of ingestion.
5. PHARMACOLOGICAL PROPERTIES
5.1. Pharmacodynamic Properties
Fluocinolone acetonide is a synthetic anti-inflammatory corticosteroid. Its mechanisms of action are related to vasoconstriction and suppression of membrane permeability, mitotic activity, the immune response and release of inflammatory mediators.
Neomycin sulphate is an aminoglycoside antibacterial agent, which inhibits bacterial protein synthesis.
5.2. Pharmacokinetic Properties
The extent of percutaneous absorption of fluocinolone acetonide is determined by many factors including the vehicle, the integrity of the epidermal barrier and the use of occlusive dressings. Following absorption, fluocinolone acetonide is metabolised primarily in the liver and excreted by the kidneys.
Neomycin is not absorbed through intact skin. It is readily absorbed from large denuded, burned or granulating areas. Excretion is then as unchanged drug.
5.3. Preclinical Safety Data
None stated.
6. PHARMACEUTICAL PARTICULARS
6.1. List of Excipients
Propylene Glycol Ph.Eur Lanolin
Liquid Paraffin Ph.Eur White Soft Paraffin BP
6.2. Incompatibilities
None known.
6.3. Shelf Life
42 months.
6.4. Special Precautions for Storage
Store below 25°C.
6.5. Nature and Contents of Container
Unlacquered, latex banded collapsible aluminium tube (30gm).
6.6. Instruction for Use/Handling
None stated.
7 MARKETING AUTHORISATION HOLDER
GP Pharma Ltd ARC Progress Mill Lane Stotfold Bedfordshire SG5 4NY United Kingdom
8. MARKETING AUTHORISATION NUMBER
PL 19877/0022
9. DATE OF FIRST AUTHORISATION/RENEWAL OF AUTHORISATION
6 August 2004
10 DATE OF REVISION OF THE TEXT
15/09/2014